The University of Kansas Medical Center's Division of Medical Oncology and Division of Hematologic Malignancy and Cellular Therapeutics (HMCT) in the Department of Internal Medicine offer a three-year combined fellowship program accredited through the Accreditation Council for Graduate Medical Education. This program, when completed successfully, provides board eligibility in both Hematology and Medical Oncology. The University is affiliated with the Kansas City Veterans Affairs Medical Center. Fellows spend one fourth to one third of their time at the Kansas City VA during the fellowship program.
The Fellowship Program includes activities in both the outpatient and inpatient settings. Emphasis is placed on current practice of the specialty with outpatient care and continuity of care in an interactive multidisciplinary environment. Fellows are placed in specialty driven continuity clinics that allows them to follow patients longitudinally. In addition to continuity clinic, our fellows also rotate through other specialties of hematology and oncology clinics. Fellows receive exposure to a highly active Blood and Marrow Transplant Program, including autologous, allogeneic and unrelated donor transplants.
In addition, they rotate through our large Breast Cancer Prevention Program, clinical research phase I program for drug development trials, basic and translational research. All fellows are required to write two manuscripts during their 3 year fellowship.
Fellowship is part of The University of Kansas Cancer Center's National Cancer Institute Designated Cancer Center (NCICC) http://www.kucancercenter.org/. Fellows are expected to pick one of the 3 tracks clinical track, clinical research track, basic/translational research track) by mid-year of their first year of training. This will allow proper planning for 2nd and 3rd year of their program. Fellows are expected to participate and spend significant time in research including writing phase I or phase II clinical trials with faculty mentors. If prior experience or interest matches with translational or basic research program, there will be an opportunity to spend up to 18 month in an appropriate research lab. Clinical research track will have a block of time at phase I program to explore and learn early phase trial development and patient enrollment in early phase trials.
A portion of time is spent on electives, which include radiation therapy, blood banking, and palliative care. We are a member and participant of some of the large national cooperative clinical trials groups, Southwest Oncology Group (SWOG) and NRG Oncology. Our faculty research interests are diversified. These research interests include clinical research (Phase II and Phase III program), Phase I research program, translational and basic research in various fields as well as cancer prevention research. If there is more interest in our research program for fellowship training, please contact the program director for further details.
Prakash Neupane, M.D.
Associate Professor of Medicine
Director, Hematology Oncology Fellowship Program